Since follistatin, an activin A inhibitor, significantly blocked tumor progression in vivo, we can reasonably assume that new lines of therapies targeting lung AMs in tumors will become a promising approach for eradicating lung cancers in the future. This evidence concerns the gene FST and lung cancer.